To the Editor: In an interesting study, Kark Rickels, M.D., et al. (1) demonstrated the usefulness of imipramine in a benzodiazepine discontinuation program for patients with generalized anxiety disorder. Low anxiety scores (Hamilton Anxiety Rating Scale score: mean=12.5, SD=6.3) at baseline and at the 12-month follow-up and the fact that only 11 (21.2%) of 52 patients required pharmacotherapy (tricyclic antidepressants or selective serotonin reuptake inhibitors) to treat their anxiety symptoms makes one suspect that the majority of the subjects had either a mild form of generalized anxiety disorder or benzodiazepine dependence. This poses a limitation on the generalizability of the results. Maintenance therapy for generalized anxiety disorder is recommended for at least 1 year after control of anxiety symptoms has been achieved (2), and benzodiazepine dependence is known to occur at therapeutic doses (3).